In a long-running court battle over PCSK9 antibodies, Amgen lost the company’s bid to uphold patent claims for the cholesterol drug Repatha against rival drug Praluent, developed by Sanofi and Regeneron.

The Federal Trade Commission filed a complaint in federal court against Vyera Pharmaceuticals, the company formerly known as Turing Pharmaceuticals that Martin Shkreli founded, alleging an “elaborate anticompetitive scheme to preserve a monopoly” on Daraprim.

The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found.

Teva and Novartis’ Sandoz are contesting charges stemming from a multi-state lawsuit alleging that a number of generic drugmakers conspired to manipulate prices on more than 100 drugs.

Australia’s competition watchdog said the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc.’s local unit used the company’s market power to limit competition for the cholesterol-lowering drug Lipitor.

A groundbreaking deal between Allergan Plc and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts said, potentially dealing a blow to generic competition.